Programmed cell death ligand 1 (PD-L1) expression on the tumor cell surface was shown not to be a reliable predictive biomarker for response or survival as checkpoint inhibitors also are effective in patients with PD-L1 negative tumors [5–7]. This evidence concerns the gene CD274 and neoplasm.